Argentina 
Asia-pacific 
Austria 
Brazil 
England 
Germany 
Hong Kong 
Malaysia 
Netherlands 
Poland 
Switzerland 
France 
The TRB France website showcases two decades of excellence in hyaluronic acid solutions.
It is with great pleasure that we celebrate the remarkable milestone of two decades of TRB France. We stand as one of the first companies in France to introduce intra-articular injections for osteoarthritis and ophthalmic drops containing hyaluronic acid for dry eyes. TRB Chemedica France, a subsidiary of the Swiss biotechnology group TRB Chemedica International, specializing in hyaluronic acid solutions for ophthalmology, rheumatology, orthopedics, and sports medicine, is proud to announce the launch of its updated website.
For over 20 years, TRB France has consistently developed and marketed hyaluronic acid-based solutions for ophthalmic and intra-articular use. Our range of products in the fields of rheumatology, orthopedics, and sports medicine includes OSTENIL® and VISCOSEAL®, both based on hyaluronic acid derived from fermentation, designed for intra-articular injections to combat osteoarthritis.
In the realm of ophthalmology, our HYLOVIS® product line, also based on hyaluronic acid from fermentation, is tailored for treating symptoms of dry eye and ocular surface lesions.
Our expert team of 25 dedicated professionals is committed to listening to healthcare professionals and their patients, ensuring that our products meet the highest standards of quality and efficacy.
Explore our website today to learn more about our products and the difference they can make in the fields of ophthalmology, rheumatology, orthopedics, and sports medicine.